Navigation Links
BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008
Date:9/4/2008

number of ongoing programs evaluating new forms, applications and

indications of its patent protected RADIESSE dermal filler technology.

The first new commercial product derived from these efforts is expected

to be a form of RADIESSE dermal filler with Lidocaine which may improve

comfort for patients and flow characteristics for physicians, and is

expected to be launched in the United States and Europe in calendar

year 2009.

-- RADIESSE(R) Dermal Filler Post-Market Studies: The Company has

completed and submitted to FDA the results of two post-approval studies

for RADIESSE filler -- a three-year post-approval open-label follow-up

to the pivotal nasolabial fold study to evaluate the long-term safety

and duration of effect with RADIESSE filler, and a study to assess the

safety of RADIESSE dermal filler in nasolabial folds in persons of

color. In the three-year study in nasolabial folds, more than 30% of

treated nasolabial folds were rated by the treating investigator as

improved in patients who were two to three years from their last

injection. No long-term product related adverse events or

delayed-onset adverse events were reported in the study. In the

persons of color study, observed adverse events were typical of dermal

fillers such as redness, swelling, and bruising, and the study found

that RADIESSE dermal filler is safe for use in persons of color. These

studies were conducted pursuant to the requirements of the FDA

associated with the approval for RADIESSE dermal filler for facial

folds and wrinkles.

-- POLIDOCANOL: As announced in a separate press release today, positive

results from the Phase III clinical trial of Polidocanol (European

trade name Aethoxysklerol(R)), a sclerotherapy product for the

treatment of spid
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Permian Plastics, http://www.permianplastics.com began ... Missouri, area on October 24th, 1994. Since then, ... injection molder in the Midwest. The company operates horizontal ... to many Fortune 500 clients. , Permian Plastics is ... the way, from concept to completion, going the extra ...
(Date:10/2/2014)... At a time when many are feeling their laboratory ... new kind of squeeze aimed at containing lab costs by ... Rite™ Wash Bottle , catalog no. F11717-0030. Innovative in shape ... the waste of reagents, solutions and other liquids by allowing ... squeeze when compared to standard 500ml bottles, its unique shape ...
(Date:10/2/2014)... 2, 2014  NKT Therapeutics today announced that ... Fast Track designation to NKTT120, the company,s lead ... cell disease.  NKTT120 is a humanized monoclonal antibody ... cell that has been demonstrated to be a ... of sickle cell disease.  Fast Track designation is ...
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider of ... today announced its participation in the 2014 Big Data ... solutions provide semantic linkage and meaning to Big Data ... manage diverse data. Ben Szekely, vice president and founding ... “life sciences data lake” and an approach for collecting ...
Breaking Biology Technology:Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2
... Boston Scientific Corporation (NYSE: BSX ) today ... and Drug Administration (FDA) to market its TAXUS(R) Liberte ... deliverable, next-generation drug-eluting stent (DES) specifically designed for treating ... in vessels as small as 2.25 mm in diameter ...
... Network Sciences, Inc. (GNS) today announced that it ... University of California San Francisco Cancer ... drug development across several therapeutic areas. This collaboration ... of UCSF with the computational expertise and supercomputer-driven ...
... Cell Institute (RSCI) today announced its 2009 Science Advisory Board. Once ... world-leader and has a world-first to his credit. , ... Dallas, Texas ... http://www.RepairStemCells.org , a Dallas, Texas-based stem cell global public affairs organization founded ...
Cached Biology Technology:FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results 2RSCI Announces World-Leading Stem Cell Science Advisory Board 2RSCI Announces World-Leading Stem Cell Science Advisory Board 3
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the largest international study to date into the genetic basis ... disease and provide evidence that large-scale genetic studies can assist ... as rheumatoid arthritis. The study, conducted by Dr. Robert ... Institute in the USA and Dr. Yukinori Okada from the ...
... a recent study published in the Neural Regeneration ... Li and team from Zhongshan School of Medicine, Sun ... BACE1, the key enzyme in amyloid beta protein (Aβ) ... construct a short hairpin (shRNA) expression plasmid against the ...
... is in ideal cardiovascular health, according to the new CANHEART ... CMAJ ( Canadian Medical Association Journal ). Cardiovascular ... leading cause of death in Canada. "A large proportion ... trend has not changed in the past decade," says senior ...
Cached Biology News:Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 3
... The AccuSpot automates LC microfractionaction, spotting and ... the AccuSpot system, LC eluent can be ... in trace amounts (eg.50nl). Matrix solutions can ... preparation of target plated for MALDI-TOF-MS measurements. ...
Glycerokinase; from Bacillus stearothermophilus...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
...
Biology Products: